Table 5 |
||||||
|
Early signs of infection according to the skin preparation procedure used and the known risk factors. Number of patients (%) |
||||||
|
48 hours after insertion |
Maddox index 0 |
Maddox index 1–2 |
Maddox index 3–5 |
|||
|
A |
B |
A |
B |
A |
B |
|
|
|
||||||
|
PVCs |
81 |
72 |
26 |
20 |
2 |
2 |
|
Men |
51 (63) |
46 (64) |
17 (65) |
11 (55) |
2 (100) |
2 (100) |
|
Age > 69 years |
28 (34) |
28 (39) |
8 (31) |
8 (40) |
1 (50) |
1 (50) |
|
Immunosuppression |
20 (25) |
20 (28) |
5 (19) |
5 (25) |
- |
- |
|
Insertion site |
||||||
|
Back of the hand |
14 (17) |
9 (12) |
3 (11) |
1 (5) |
- |
- |
|
Elbow |
5 (6) |
5 (7) |
1 (4) |
2 (10) |
- |
- |
|
Forearm |
62 (76) |
55 (76) |
20 (77) |
17 (85) |
2 (100) |
2 (100) |
|
Nature of PVC |
||||||
|
Polyurethane |
52 (64) |
44 (61) |
11 (42) |
12 (60) |
2 (100) |
1 (50) |
|
Polyvinyl chloride |
13 (16) |
8 (11) |
9 (35) |
4 (20) |
- |
1 (50) |
|
Teflon |
18 (22) |
20 (28) |
4 (15) |
4 (20) |
- |
- |
|
Solutes perfused |
||||||
|
Antibiotics |
31 (38) |
26 (36) |
9 (35) |
7 (35) |
- |
2 (100) |
|
Anticancer drugs |
20 (25) |
18 (25) |
4 (15) |
4 (20) |
- |
- |
|
Lipids |
2 (2) |
- |
- |
2 (10) |
- |
- |
|
Blood products |
3 (4) |
- |
1 (4) |
1 (5) |
- |
- |
|
|
||||||
|
72 hours after insertion |
Maddox index 0 |
Maddox index 1–2 |
Maddox index 3–5 |
|||
|
A |
B |
A |
B |
A |
B |
|
|
|
||||||
|
PVCs |
44 |
41 |
15 |
14 |
4 |
1 |
|
Men |
30 (68) |
28 (68) |
8 (53) |
8 (57) |
3 (75) |
1 (100) |
|
Age > 69 years |
17 (39) |
15 (37) |
7 (47) |
4 (29) |
1 (25) |
- |
|
Immunosuppression |
12 (27) |
12 (29) |
5 (33) |
6 (43) |
- |
12 (27) |
|
Insertion site |
||||||
|
Back of the hand |
6 (14) |
4 (10) |
4 (27) |
- |
1 (25) |
- |
|
Elbow |
3 (7) |
3 (7) |
1 (7) |
1 (7) |
- |
- |
|
Forearm |
34 (77) |
32 (78) |
9 (60) |
13 (93) |
3 (75) |
1 (100) |
|
Nature of PVC |
||||||
|
Polyurethane |
26 (59) |
23 (56) |
5 (33) |
5 (36) |
1 (25) |
1 (100) |
|
Polyvinyl chloride |
8 (18) |
5 (12) |
4 (27) |
3 (21) |
3 (75) |
- |
|
Teflon |
11 (25) |
13 (32) |
5 (33) |
6 (43) |
- |
- |
|
Solutes perfused |
||||||
|
Antibiotics |
20 (45) |
13 (32) |
5 (33) |
3 (21) |
3 (75) |
- |
|
Anticancer drugs |
12 (27) |
12 (29) |
5 (33) |
5 (36) |
- |
- |
|
Lipids |
- |
- |
1 (7) |
1 (7) |
- |
- |
|
Blood products |
- |
- |
2 (13) |
- |
- |
- |
|
|
||||||
|
van der Mee-Marquet for the Bloodstream infection Study Group of the Relais Régional d'Hygiène Hospitalière du Centre BMC Anesthesiology 2007 7:1 doi:10.1186/1471-2253-7-1 |
||||||
